Jefferies Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Jefferies Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-33,500	Closed	-$4.27M	–	1743
2021 Q4	$4.27M	Hold	33,500	–	–	0.03%	516
2021 Q3	$4.36M	Hold	33,500	–	–	0.03%	478
2021 Q2	$5.95M	Buy	+33,500	New	+$5.8M	0.04%	415
2016 Q1	–	Sell	-13,000	Closed	-$1.83M	–	2404
2015 Q4	$1.83M	Buy	+13,000	New	+$1.8M	0.01%	905
2015 Q1	–	Sell	-20,000	Closed	-$3.27M	–	2245
2014 Q4	$3.27M	Buy	+20,000	New	+$3.32M	0.02%	541
2013 Q3	–	Sell	-400,000	Closed	-$27.5M	–	2058
2013 Q2	$27.5M	Buy	+400,000	New	+$24.4M	0.3%	44

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Jefferies Group's JAZZ Position: Q1 2022 in Review

Jefferies Group sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 2,781 shares — an estimated $354K sold.

Jefferies Group first reported a position in JAZZ in Q2 2013 and held it in 27 quarters. The position peaked at $7.02M in Q3 2015. 461 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

Jefferies Group reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Jefferies Group sold 2,781 Jazz Pharmaceuticals shares in Q1 2022, an estimated $354K.
Jefferies Group first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 27 quarters.
Jefferies Group's Jazz Pharmaceuticals position peaked at $7.02M in Q3 2015.
461 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.